StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for BBLG yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.27 | $1.27 | +0.00% | 0.0M |
| 05-18 | $1.30 | $1.25 | -3.85% | 0.0M |
| 05-19 | $1.33 | $1.26 | -5.26% | 0.0M |
| 05-20 | $1.25 | $1.23 | -1.60% | 0.0M |
| 05-21 | $1.23 | $1.25 | +1.63% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2021 2021-06-30 | Q1 2021 2021-03-31 | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 |
|---|---|---|---|---|
Revenue | $1.07B | $1.07B | $1.07B | $1.07B |
Operating Income | $-412.81K | $-180.92K | $-825.01K | $-618.58K |
Net Income | $-491.90K | $-431.75K | $-1.82M | $-1.37M |
EPS (Diluted) | $-0.32 | $-0.15 | Not available | Not available |
Total Assets | $4.44K | $71.17K | $0.00 | Not available |
Total Liabilities | $14.62M | $14.20M | $13.69M | $13.24M |
Cash & Equivalents | $4.44K | $71.17K | Not available | $2.46K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 30.68M | 30.68M | 12.27M | 30.68M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.